

IBD BioResource Panel Descriptive based on the Montreal classification¹ (cut-off date March 2019)

Diagnosis (%)	
Crohn's disease	49
Ulcerative colitis	46
IBD Unclassified	3
Missing	2



Age at diagnosis (%)		
A1	< 17 years	8
A2	17-40 years	58
A3	> 40 years	33
Missing		4



Ulcerative colitis (UC) Extent n (%)		
E1	Ulcerative proctitis	1441 (14)
E2	Left-sided UC	3998 (39)
E3	Extensive UC	2867 (28)
Missing		1948 (19)

Crohn's disease Location n (%)		
L1	Terminal Ileum	3508 (34)
L2	Colonic	2659 (26)
L3	Ileo-colonic	2914 (28)
L4	Upper GI	593 (6)
Missing		646 (6)
<i>Peri-anal involvement</i>		<i>3022 (29)</i>

Crohn's disease Behaviour n (%)		
B1	Non-Stricturing/penetrating	6424 (62)
B2	Stricturing	2080 (20)
B3	Penetrating	933 (9)
Missing		1000 (9)



*'Colectomy' includes proctocolectomy, sub-total colectomy and segmental colectomy; 'peri-anal surgery' includes abscess drainage, seton insertion and fistula repair; 'ileo-jejunal surgery' includes resections and strictureplasties; and 'ileo-caecal resection' includes right hemicolectomy.

*Total number of patients who have been treated with each biologic therapy (one patient can have received more than one therapy)

Biologics	CD (n)	UC (n)	IBDU (n)
Infliximab	4078	1560	128
Adalimumab	3147	651	63
Golimumab	27	109	6
Vedolizumab	606	647	32

*Total number of patients who have been treated with each thiopurine

Immunosuppressant	CD (n)	UC (n)	IBDU (n)
Azathioprine	7693	4355	246
Mercaptopurine	1865	1056	61

Reference

¹Satsangi J, Silverberg MS, Vermeire S, Colombel JF. Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006 Jun; 55(6): 749-53.